Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Eda Çapkın"'
Publikováno v:
Heliyon, Vol 9, Iss 9, Pp e19469- (2023)
The controlled orientation of biomolecules on the sensor surface is crucial for achieving high sensitivity and accurate detection of target molecules in biosensing. FcγRI is an immune cell surface receptor for recognizing IgG-coated targets, such as
Externí odkaz:
https://doaj.org/article/67b7bb81e0bd4aa3aef1753eef503f7c
Autor:
Büşra Gürel, Eda Çapkın, Ayhan Parlar, Aylin Özkan, Meltem Çorbacıoğlu, Duygu Emine Dağlikoca, Meral Yüce
Publikováno v:
Scientia Pharmaceutica, Vol 90, Iss 2, p 36 (2022)
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provi
Externí odkaz:
https://doaj.org/article/a00f14c450b247d2a048b9f417756e39
Publikováno v:
Current medicinal chemistry.
Abstract: Viral infections can cause fatal illnesses to humans as well as animals. Early detection of viruses is therefore crucial to provide effective treatment to patients. Recently, the Covid-19 pandemic has undoubtedly given an alarming call to d
Drug-loaded magnetic nanoparticles have been developed because of the advantages of specific drug targeting in cancer treatment. Pemetrexed (PEM) is a multi-targeting antifolate agent that is effective for the treatment of many cancers, for example,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86efdc7e1f63239c527ca4ec2eea7a02
https://hdl.handle.net/11454/63205
https://hdl.handle.net/11454/63205
Autor:
Güliz, Ak, Didem, Aksu, Eda, Çapkın, Özge, Sarı, Ilgın, Kımız Geboloğlu, Şenay Hamarat, Şanlıer
Publikováno v:
Preparative biochemistrybiotechnology. 50(3)
Drug-loaded magnetic nanoparticles have been developed because of the advantages of specific drug targeting in cancer treatment. Pemetrexed (PEM) is a multi-targeting antifolate agent that is effective for the treatment of many cancers, for example,
Autor:
Busra Gurel, Melike Berksoz, Eda Capkin, Ayhan Parlar, Meltem Corbacioglu Pala, Aylin Ozkan, Yılmaz Capan, Duygu Emine Daglikoca, Meral Yuce
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1571 (2022)
Avastin® is a humanized recombinant monoclonal antibody used to treat cancer by targeting VEGF-A to inhibit angiogenesis. SIMAB054, an Avastin® biosimilar candidate developed in this study, showed a different charge variant profile than its innovat
Externí odkaz:
https://doaj.org/article/d639b8ba82f649c6b9f86058a8458ef5